Investing in yourself is not just financial, it included personal development activities such as exercise or hobbies. The stories we will hear will hopefully provide some inspiration and spark the interest of a broader discussion. Investing in yourself means different things for all of us and changes can be big or small.

This event is a lead-up to the LES Annual Meeting and another opportunity to expand your networking even before the annual meeting begins.

Moderator
Dana Matzen, Chair of the LES Life Sciences Sector, VP Business & Corp. Development, IntelGenx

Speakers
Jay Kugler DeYoung, Principal, Fish & Richardson
Heather R. Kissling, Partner and Prosecution Practice Chair, Marshall & Gerstein
Kamil Ali-Jackson, Chief Legal Officer and Co-Founder, Aclaris Therapeutics

This panel will discuss the current state of the law, its impact on protecting network-based inventions, and practical strategies for obtaining enforceable patents in this area.

Speakers
Michael S. Borella, Ph.D., Partner, McDonnell Boehnen Hulbert & Berghoff LLP
Dr. Tom Bradicich, Hewlett Packard Enterprise Company
Michael Fisher, Esq., Counsel, Dechert LLP
Ivan Kirchev, Esq., Senior Counsel, Hewlett Packard Enterprise
Michael A. Koptiw, Partner, Condo Roccia Koptiw, LLP

There are multiple examples of such fields in the life sciences: emerging infectious diseases, neglected tropical diseases, antibiotic resistance, and ultra-orphan genetic diseases and cancers. Public discourse has become stridently anti-patent in some of these fields, driven by the simplistic appeal of “access to medicines” and “drug pricing.” We will address solutions ranging from alternatives to traditional milestones/royalties, liability and indemnity protections, and public funding.

Speakers
Sung Hee Choe, MPH, Director, FasterCures, A Center of the Milken Institute
Gillian Fenton, Esq., CLP, Senior Counsel, Vaccines Legal Operations, GSK Vaccines
Julie Barnes-Wiese, J.D., CLP, Executive Director, GHIAA
Amy Finan, CEO, The Sabin Vaccine Institute
Emma Wheatley, Deputy GC, Head of Collaborations, Coalition for Epidemic Preparedness Innovations (CEPI)

The panelists representing different industries, High-Tech, Life Sciences, and Consumer Products, will present their perspectives on monetizing patents in the secondary market within their industries particularly as it relates to buying/selling patents, present industry risks and rewards (perceived or real), valuation approaches applied, common channels used, examples of some major deals, and any specific do’s and don’ts for such a transaction.

Speaker
Sandeep Agarwal, Vice President, Acquisitions and BD, Xperi Corporation
Kevin Brown, Co-Founder, President and CEO, Accencio, LLC
Matthew Fitzpatrick, Vice President – Associate General Counsel & Deputy Chief Patent Counsel, The Procter & Gamble Co.
Nishant Jaiswal, Senior Counsel | IP Licensing, Hewlett Packard Enterprise

Speaker
Adrian Cyhan, Partner, Dinsmore & Shohl LLP
Bethany Loftin, Interagency Policy & iEdison Specialist, National Institute of Standards and Technology
Nicole Nan, Partner, Dinsmore & Shohl
Michael Perham, Director, Innovations and External Relations, HHMI / Janelia Research Campus
Jaysen Rajkomar, Senior Legal Counsel, Toyota Research Institute, Inc.
Laleh Shayesteh, Sr. Licensing Officer and Asst Director of Administration, University of California, Berkeley

Speakers
Jeffrey Bartholomew, JD, Shareholder, RWO (Robinson Waters & O’Dorisio, P.C.)
Mihaela Bojin, Associate Director, University of Iowa Research Foundation
Aaric Eisenstein, MBA, Vice President of Licensing Strategy, PMC (Personalized Media Communications)
Ron Laurie, JD, Managing Director, Inflexion Point Group
Mike Pellegrino, MBA, Founder and President, Pellegrino & Associates

Because of this high risk, larger established companies can be hesitant to license the technology. As a result, many university-owned inventions would language languish if not for innovative, risk-taking inventors who spin out companies for the purpose of developing intellectual property they created as university faculty, staff, or students. While the scientists, engineers, and clinicians who become inventor-founders can supply the company with the technical knowledge needed to advance the invention, spinouts regularly face significant challenges in two other critical areas—operating a cash-strapped organization and developing the business development skills to grow the enterprise. Such financial and managerial struggles can be particularly difficult to overcome in the first few years of operation, and it is all too common for a spinout to fold before a product can be commercialized. To support their university entrepreneurs, many TTOs have crafted a suite of favorable deal terms and business development support services to offer to spinouts to help the companies survive these challenging early years.

Speakers
Patrick Govang, Director, Innovation Partnerships, Cornell University
Natasha Jones, Commercialization Manager, University of Kentucky
Leena Prabhu, Ph.D., Associate Director, Washington University in St. Louis
John Puziss, Ph.D., Director of Business Development, Yale University

Through its licensing business, Qualcomm is able to make its breakthroughs available to licensees around the world, enabling industry ecosystems, accelerating the growth of wireless industry, reducing barriers to entry, encourage vertical and horizontal competition, level the playing field, and ultimately make the benefits of mobile technology available to more people, more efficiently, and across socio-economic classes.

Keynote Speaker
Fabian Gonell, Senior Vice President, Licensing Strategy and Legal Counsel, Qualcomm

Our panelists are gene and cell therapy leaders in translational academic science, technology commercialization, contract development and manufacturing, and biotechnology. We will discuss numerous topics including evaluation of new technologies, effective partnership models, technology access considerations and unique approaches to technology protection to support translational development and commercialization of new cell therapy and gene therapy products. Special focus will be given to addressing unique benefits and challenges of partnering with academic research and medical centers and CMDOs and how to maximize value and benefit for each party in these partnerships. We will also discuss perspectives on the future of the gene and cell therapy field, including exciting areas for development as well as the biggest issues and challenges that urgently need to be addressed. In each case, we will discuss how effective partnering and deal structuring is critical for moving translational product development forward with the aligned goal of bringing new safe and effective gene and cell therapies to patients in need.

Speaker
Usman Azam, President & CEO, Tmunity Therapeutics Inc.
James Bowen, Executive Director, Corporate Alliances, University of Pennsylvania
Carl June, Professor, University of Pennsylvania
Ugur Sahin, CEO, BioNTech
Andy Topping, Chief Scientific Officer, FUJIFILM Diosynth Biotechnologies

Panelists will provide a brief overview of the various technologies in use and their various applications. This will be followed by a discussion of recent issues the panelists have experienced including business, ethics and intellectual property. Audience participation and input is welcome.

Speakers
Kate Gaudry, Partner, Kilpatrick Townsend
Susan Hallen, PE, MBA, IP Management Solutions Lead, IBM
Stephen Kabakoff, Partner, Miller & Martin
Sean O’Connor, Professor of Law & Executive Director, George Mason University, Center for Protection of IP (CPIP)

Particular attention will be paid to emerging technology areas, patent pools, etc., from both the implementation and execution perspective.

Speakers
Todd Sigler, Principal, Green Hasson Janks
Ozer Teitelbaum, Managing Director, Ocean Tomo, LLC
Keith Walker, Director, Intellectual Property Licensing, International Game Technology

With its strong commitment to the fundamental sciences and its applications, these innovation factories produce large numbers of impactful technologies that could be readily adopted by industry. Federal Laboratories are mission driven (as compared to revenue driven) and they can offer low cost, flexible licensing terms tailored to fit a business strategy. Select companies that have engaged the Laboratories either for collaborative research or technology transfer, continually return for more. Yet, to many commercial entities and/or entrepreneurs, working with Federal Laboratories may appear to represent insurmountable challenges and opaque processes hindering effective engagement. This panel will demystify the processes of engagement with the Federal Laboratories, provide examples of successes, and explore the various federal programs available to industry to effectively engage with the Laboratories. Speakers represent technology transfer experts from the Laboratories, entrepreneurs and industrial collaborators, and venture fund managers, who will share their experiences in accessing some of the most fascinating technologies of the future.

Speakers
Nena Golubovich, Director, Physical Sciences, IP Group, Inc
Marcos Gonzales Harsha, Deputy Director, US Department of Energy, Office of Technology Transfer
Kannan Krishnaswami, Technology Commercialization Manager, Pacific Northwest National Laboratory
Jason Stolworthy, Director of Technology Deployment, Idaho National Laboratory

Kent Richardson has been producing the authoritative secondary patent market report for almost ten years. The Richardson Oliver Insights annual report will be coming out in December, but you can get early access to some of that information now. Come find out the answers to the above questions and more.

Speakers
Rob Guay, LLB, Senior Counsel, Intellectual Property, Shopify Inc.
Joe Kucera, JD, Director, IP Strategy, Pure Storage Inc.
Kent Richardson, CEO, Richardson Oliver Insights

Speaker
Yu-An Chang, Counsel, Hogan Lovells
Yu Sarn Chiew, Partner, Yusarn Audrey
Qing Lyu, Attorney, HL Fidelity

In the presentation, the panelists will provide their on the ground assessments and predictions, and those will be compared and contrasted with the computer-generated summaries.

Speaker
Kimberly Honeycutt, PhD, Assistant General Counsel – Intellectual Property, Elanco Animal Health
Kyle Kimble, PhD, VP of Business Development and Licensing, Inceptor Bio, LLC
CG Moore, PhD, McBee Moore & Vanik

Tech powerhouse Shenzhen and manufacturing center Zhuhai are amongst these cities. This area is reportedly home to 70 million people, produces 37% of China’s exports, and generates approximately $1.5 trillion in GDP each year. With the goal of significantly integrating the financial, regulatory, and technological sectors, there is immense potential for commercialization and investment. Part of the appeal to this fledgling tech hub is the public listing opportunities. It was reported that $18.5 billion in IPOs in Hong Kong as of mid-2019. We will take a comparative look at various stock exchanges (including Hong Kong and Shanghai). Learn about the opportunities, developments, and challenges this integrated hub for international business and finance.

Speakers
Albert Wai-Kit Chan, Founder and Director, United States-China Intellectual Property Institute, Inc.
Dongmin Chen, Ph.D., Chair Professor, Institute for Advanced Interdisciplinary Studies, Peking University
Tomson Lee, Senior Tech Transfer Officer, City University of Hong Kong
Alan Paau, Ph.D., Sole Proprietor, iElevate
Joseph Wing-On Tam, Ph.D., Founder & Chairman, JT Technology and Consultant Ltd.

Discussion of mechanisms for collecting data (although a full discussion of data privacy and security rights is not intended). Overview of data use agreements including the Creative Commons License, Open Data Commons Attribution License, Community Data License Agreement, GPLv3 License, and Microsoft’s proposals around the Open Use of Data Agreement.

Speakers
Derek Stettner, Partner, Michael Best & Friedrich
Ryan Sulkin, Partner, Michael Best & Friedrich

Speakers
Tom Chia, Senior Director of Patents & Corporate Development, Via Licensing
Sean Clark, Director of North America IPR & Licensing, Ericsson
Efrat Kasznik, President, Foresight Valuation Group
Sam Wiley, Director, Global Business Intelligence Solutions, VALUENEX Inc.

• Blockchain technologies as an official digital technology used by public authorities and private business to manage, disposal, register, verify and examine IP assets;
• Artificial Intelligence as an efficient way to run patent examination and search.
• 3D digital models for trademarks, inventions and design – new digital instrument to demonstrate and handle different kind of IP.

Speakers
Boris Gerasin, Head of Patent Team, Public joint stock company «Sberbank of Russia»
Andrey Inshakov, Head of Patent Department, Yandex
Sergey Medvedev, Partner, Gorodissky & Partners
Alexander Sysoenko, Head of the DLT Development Center, Federal Institute of Industrial Property (FIPS) /RU PTO
Sergey Vasiliev, Senior Lawyer, Gorodissky & Partners

However, some of the potential downsides of using these third party tools is that they tend to be very patent office examiner-specific, and it’s often hard to combine their data with internal company data. Being able to seamlessly marry these two data sources has been shown to provide stronger insights into inventor behaviors that lead to better IP, allowing for more proactive corporate IP best practices, rather than later reactionary decision-making.

Hear from a company in the unique position of being able to use AI and mass dataset statistical analysis tools, along with internal AI experts, to merge their valuable internal IP data with patent office prosecution data to gain stronger insight into how they can better align their IP generation processes to push for higher quality IP, while working to mitigate repeats of past mistakes. Other panelists that provide customized analyses work for their customers will also give their valuable thoughts on this topic.

Speaker
Paul Ashcraft, Intellectual Property Liaison, Halliburton
Candice Landry, Commercial Manager, Chevron
Megan McLoughlin, Esq., Director of Product Management, LexisNexis Intellectual Property
Mark Stignani, Analytics Practice Group Chair, Barnes & Thornburg

Speakers
Barbara Bates, Global CEO, Hotwire
Edgar Baum, Founder & CEO, Avasta Inc
Mary Filippelli, CPA, Independent Board Member, Corporate Director
Justin Fogarty, BA, LLB, LLM, Founder & Managing Director, STS Agility
MK Marsden, Chief Advisor, Avasta Inc

Mobile communication technology is making its way in cars and sensors and medical devices and on the factory floor. Bioengineering is bringing back mobility to amputees and people who suffered spinal injuries. Artificial intelligence and machine learning are having an unprecedented impact on virtually every field of knowledge. Banks and financial institutions are transforming themselves into technology companies.

Several industries are, and have been for several years now, on a virtuous and very prolific convergence trajectory. How does convergence change paradigms and best practices when it comes to tech transfer and licensing? Through a multidisciplinary panel of licensing and tech transfer professionals from different sectors such as automotive, banking, life science, ICT, we will explore possible similarities between only apparently separate innovation areas, point out peculiarities and differences, learn from each other, and identify areas of potential cross-pollination. Furthermore, the panel will discuss how convergence will impact such licensing practices.

Speaker
John Carney, Managing Director, China IP Exchange, LLC
Bowman Heiden, Co-Director, Center for Intellectual Property
Matteo Sabattini, Director IP Policy, Ericsson Inc.
Richard Vary, Partner, Bird & Bird

U.S. Design patents are increasingly becoming strategic value-added components to patent families and portfolios. Additionally, U.S. Design Patents are being increasingly licensed and litigated.

This session will explore strategies for protecting emerging technologies through U.S. Design Patent prosecution, licensing, and enforcement.

It should also be noted that while this session could be a stand-alone session, the substance of this session could also be combined in a broader session addressing “Design Protection on Emerging Technologies” in general.

Speaker
John Davis, Partner, Wood Herron & Evans, LLP
Michele Gunness, Senior Technology Development Manager, Oregon Health & Science University
Michele Tyrpak, Associate Director, University of South Florida

Speakers
Ben Beaven, Global Director of Strategic Development, Getty Images
Barry Brager, CLP, RTTP, Managing Partner, Perception Partners
Charles Macedo, Partner, Amster, Rothstein & Ebenstein, LLP
Nicole Spence, Esq., IP Attorney, Cross Brands IBM

“Efficient infringement” is a relatively new topic that explains how incumbents and defendants choose to avoid paying because it is cheaper to delay by way of litigation and tactics such as negative PR and lobbying. Individual companies large and small are victims of efficient infringement. They can try to outlast the deep-pocketed infringer. Or, they can turn to secondary market resources for cash and other support and at scale. This panel provides information about what efficient infringement is and what options exist in the secondary market.

Speakers
Marc Booth, Chief Intellectual Property Officer, Acacia Research Corporation
Peter Harter, Founder, The Farrington Group
Jay Knobloch, EVP of IP.NuCurrent, Inc.
Julie Turner, Partner Emerita, Turner Boyd LLP

Topics to be discussed will include:

• Understanding key accounting principles and their differences
• Financial Statement versus License Agreement accounting
• Accrual versus Cash accounting
• Income statement revenue recognition rules
• Affiliate companies and consolidation of financial statements
• Royalty base calculation do’s and don’ts
• Discounts and allowances and what that means in accounting terms
• Transfer pricing
• Valuation inputs
• Audit clause record request
• Going concern issues
• and more

Speaker
Debora Stewart, Managing Director, InvotexIP

These data, combined with advanced analytics software and computer hardware able to manipulate these large datasets, have begun to elucidate trends in patent prosecution that (when combined with in-house data and the proper assumption frameworks) may give IP practitioners insights that can help create better IP and save filers money.

This presentation will provide a brief overview of new patent analytics tools, some concrete examples of patent office data analyzed to produce cost-saving decision-points during application prosecution, and where the field of IP analytics is moving into the future.

Speakers
Rocky Berndsen, Head of Patent Analytics, Harrity & Harrity, LLP
Barry Brager, CLP, RTTP, Managing Partner, Perception Partners, Inc.
Shayne Phillips, Managing Member, Six Points Consulting, LLC

Matthew Weinstein, Director, Legal – Patents and Open Source, Accenture

The technologies are:

Protecting Data at Rest – Prof Vladimir Shpilrain, City University of New York
Ineffective security has cost untold billions and loss of life. Professor Shpilrain has developed the first viable form of FHE (Fully Homomorphic Encryption) in which data can be encrypted but still searched for keywords without the need to decrypt.

Protecting Data in Motion – Junaid Islam, Fmr. Security Architect Special Operations Command
Junaid developed the only unbreached security architecture (resistant to quantum attacks). He will explain how communication about IP can be protected.

Valuing IP in the Age of Big Data Automation – Mike Pellegrino, Pellegrino and Associates
Mike is known to the IP community for his groundbreaking work in valuing IP. He will explain the broader role of Big Data in managing IP.

An Integrated Approach to Protecting, Managing and Commercializing IP Michael Miron, Ideation Inc.
Michael will then show how each technology together can solve many of the problems of commercializing IP.
Speakers
Junaid Islam, Cybersecurity Expert, National Spectrum Consortium
Michael Miron, CEO, Ideation Inc
Mike Pellegrino, President, Pellegrino and Associates
Vladimir Shpilrain, Professor of Mathematics and Computer Science, City University of New York

They also fall within the domain of life science inventions. Machine learning can be employed to use patient data to not only track patient outcomes to therapies but also predictively diagnose diseases and patient conditions. The recent influx of data and machine learning technologies, especially related to patients has created a unique set of challenges with not only managing and commercializing such technologies but also tackling the complexities associated with individual/ patient privacy, legal, and compliance issues. This panel hopes to shed light on these complex and evolving matters.

Speakers
Dinesh Divakaran, PhD, MBA, Director, Digital Innovations, Duke University
Stephen Gardner, J.D., Partner, Quarles & Brady LLP
Angela Kujak, J.D., Senior Director of Contracts, University of California, Los Angeles
Sangeetha Raghavan, Sr. Licensing Associate, Children’s National Medical Center
Daniel Rudoy, PhD, Associate, Electrical and Computer Technologies, Wolf Greenfield

The expert panelists provide an academic and industry point of view and will provide insights into how AI will play a role in the future of the industry.

Speakers
Bruce Bloom, Chief Collaboration Officer, Healx
Raja Krishnan, Commercialization Manager, University of Kentucky
Dipanjan Nag, Chief Investment Officer, Ventech Solutions
Krishnan Nandabalan, Founder/CEO, InveniAI

Patent law deals with the legal right to protect inventions and assure the right to keep others from making, using, offering for sale, selling, and importing the claimed invention. Therefore, antitrust and IP law are perceived as conflicting as patent law could provide a meaningful exclusionary right.

To limit the power given to patent owners and prevent a complete monopoly over a certain invention, several provisions of law have been established (e.g. compulsory licenses or FRAND commitments); in this way, a balance in the best interests of patent owners and implementers could be reached in terms of technical development and pricings. However, conflicts between patent and antitrust laws may arise when patents are misused beyond their natural limits of law.
The aim of the workshop is to highlight if IP and antitrust laws should be considered as a dangerous crossroad of different competences or a useful intersection in encouraging innovation, industry growth, and fair competition.

Speakers
Garrard Beeney, Partner, Sullivan & Cromwell LLP
Roberto Dini, Founder, Sisvel
Dina Kallay, Head of Antitrust, Ericsson
John Paul, Partner, Finnegan
Jin (”Victor”) Yang, Vice President/Group General Counsel, TCL Technology Group Corporation

Deals can get bogged down (what some refer to as “deal friction”) in the initial stages of discussions because it can take several weeks to several months to reach agreement on the language of a Non-Disclosure Agreement before any confidential information is disclosed. LES believes that this deal friction results in licenses taking longer to sign and great technologies being delayed from ultimate launch as products. The lost opportunity for earlier launch costs the inventor/licensor and licensee but also results in the ultimate users not being able to benefit sooner from a product than they would have otherwise.

What is *significant* about the LES Model NDA is that a number of organizations (each called an Initial Accepting Organization or IAO) have already agreed to accept and sign *without any changes* the NDA. This session will introduce the latest version of the LES NDA and where on the LES website the Model NDA can be found.

Speakers
Halina Dziewit, Esq., Attorney, Berg Hill Greenleaf Ruscitti LLP
Stephanie Miller, Ph.D., Executive Director, Technology Transfer and Research Park Initiatives, Embry-Riddle Aeronautical University
Carol Mimura, Ph.D., Asst. Vice Chancellor, IP & Industry Research Alliances (IPIRA), U.C. Berkeley
Jay Reilly, Esq., Senior Counsel, Saul Ewing LLP
Paul Stewart, CLP, Managing Director, PASCO Ventures LLC

Moderator
Ian DiBernardo, Partner, Stroock & Stroock & Lavan LLP

Speakers

Javeed Froozan, Vice President, Research Business Development & Strategic Alliances, The Leukemia & Lymphoma Society
Thomas Axel Haag, Ph.D., J.D., Managing Partner, Haag Life Sciences Law
Kristin Hebert, Managing Partner, Caldwell Partners

Speaker
Amy Banse, Senior Vice President, Comcast Corporation
Ben DuPont, Co-Founder and Partner, Chartline Capital Partners
Sam Liggero, Professor of the Practice, Tufts University Gordon Institute

It not only will identify the cases, but also explain how each case could potentially impact the way we draft and negotiate patent license agreements and technology transfer agreements.

This is a live-only session, and it will not be recorded. To register for this session only (no access to the full meeting), please click here.

Speaker
Russell Levine, Partner, Kirkland & Ellis LLP

Speaker
Pamela Demain, President, Pamela R. Demain Consulting
Kevin Higgins, Group Lead Outlicensing, Worldwide Business Development, Pfizer
Linda Hogan, President and Founder, LLH Associates
Eric Victory, VP Global Strategic Marketing, Aurinia Pharmaceuticals

Given that national laws have become increasingly divergent in this sector over the last few years, this session will include pointers on how to optimise a PCT filing ready for divergence of strategies in the national phase. Each presenter will also draft two or three claims relating to some hypothetical inventions to compare and contrast how this is best tackled in each region.

Speakers
Helen Henderson, Ph.D, Patent Attorney, Withers & Rogers LLP
Jeffrey Morton, Ph.D., Partner, Snell & Wilmer L.L.P.
Theodore Sum, LLB, Partner, Smart & Biggar

The panel will highlight recent achievements, challenges in reaching consensus, and procedural requirements to create an ANSI-accredited American National Standard. Panelists will interact with the audience to explain why there is a need for the industry to get together to develop voluntary standards for IP management, what are the (many) steps to finalize a business process standard, and how the industry can benefit from using such voluntary standards. With a combination of representatives from committees at different stages of development, the conversation will also focus on practical aspects, common challenges, and lessons learned.

Speakers
Edgar Baum, Founder & CEO, Avasta Inc
Chris Hannon, Patent Attorney, USPTO
Craig Moss, EVP, Ethisphere
Alexandra Rehmeier, Senior Manager Intellectual Property Policy and Training, Boeing
Matteo Sabattini, Director IP Policy, Ericsson Inc.

Innovative software providers are providing solutions to support this transition. As the dust begins to settle, recent litigation tells us that this massive shift towards remote work is likely to result in compliance disputes between providers and their customers. Software developer companies and in-house counsel who are tasked with auditing, managing, and enforcing license compliance will face a new world of challenges and opportunities that will shape their business strategy. In this webinar, experienced trial attorney Bryan Mechell and senior in-house counsel will examine the issues software providers should consider today as they seek to protect and enforce the innovation they bring to market while maintaining amicable customer relationships. They will also draw upon litigation history to illustrate steps licensees can take to avoid disputes.

Speaker
Pamela Fulmer, Partner, Tactical Law Group LLP
Sara Kilian, Vice President and General Counsel, Perforce
Jhon Kong, Global Director of Compliance and License Management Services, TIBCO Software
Bryan Mechell, Partner, Robins Kaplan LLP
Brian Watson, Director, Wind River

In many cases, these data sets are linked to human subject data, and many institutions are wrestling with the question of how and even if such data should be used to develop new products and services. If so, many issues need to be considered, including patient privacy, reputation, and how access to the data is provided. Revenue from companies looking for patterns and trends in large sets of complex data continues to grow, and an ever-increasing number of start-ups are active in this space or are developing new data analysis tools. With representation from various stakeholders working in this space, the panel will provide a broad perspective on how to navigate this expanding opportunity represented by this growing field.

Speakers
Ben Dibling, Executive Director of Licensing, University of Pennsylvania
Scott Khan, PhD., Chief Information + Privacy Officer, LunaDNA
Katherine Ku, Chief Licensing Advisor, Wilson Sonsini
Kathleen Snyder, OF COUNSEL, Wilson Sonsini
Manny Stockman, Principal, Technology, Osage University Partners

In many companies, Alliance Management is implicit in the Project Manager or Business Development Manager roles but there is limited training on managing alliances. Instead, there is a focus on trying to solve problems as they arise with no proactive management. Learn how to set up the alliance and effectively manage issues to drive project success!

Speakers
Michele DeBlasio, Director, Alliance Management, Bristol Myers Squibb
John McCracken, Consultant, McCracken Pharma LLC
Brian Russo, Senior Director of Alliance Management, Pfizer, Inc.
Jay Vora, Senior Director of Alliance Management, Sangamo Therapeutics

Hear tips from attorneys who have already participated in a remote trial via video trial as to how to best present direct testimony and also cross-examine witnesses remotely. Also, attendees will have the opportunity to learn first-hand about the experience of participating in one of the first IP trials to take place via Zoom and explore why the companies in the dispute ultimately decided to test these uncharted waters.

Speakers
Daniel W. Cho, Associate, Covington & Burling LLP
Joshua P. Davis, Partner, Womble Bond Dickinson (US) LLP
Christopher Martinez, Managing Partner, StoneTurn
Neil J. Zoltowski, Partner, StoneTurn

We will address recent decisions and trends in damages law and the extent to which they are influencing patent licensing negotiations, both in industry and education licensing. This panel will also offer strategies and best practices for patent license negotiations.

The topics covered include what is influencing the reasonable royalty discussion? What impact have industry organizations like LES and AUTM had through their surveys on how to calculate it? How has 35 U.S.C. 101 affected the ability to get licensing deals done and has there been progress for licensors based on new Patent Office leadership? What types of clauses in patent licenses have corporations and universities started to include to mitigate the risk for IPRs (e.g., reasonable royalty increases if the licensee files an unsuccessful IPR)? How (if at all) are recent Supreme Court damages decisions impacting negotiations (e.g., WesternGeco on obtaining foreign damages)? Is it better in the current climate to attempt to license pre-suit or at a later date?

Speakers
Michael Lasinski, Senior Managing Director, Ankura Consulting Group, LLC
Kevin Schubert, Attorney, McKool Smith
Keith Walker, Director, Intellectual Property Licensing, International Game Technology

This panel will discuss real-world due diligence questions and best practices that everybody should know when entering into a deal with a foreign company, especially when entering markets in Asia. This panel will mainly focus on licensing agreements in the pharma/ biotech world.

Speaker
Catherine Pan-Giordano, Partner and Corporate Group Head, Dorsey & Whitney LLP
Derek Small, Partner, Luson Bioventure LLC
Paul Zhang, MBA, Partner, Bluestar BioAdvisors, LLC